# Antag Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/antag-therapeutics-aps

- Industry: Biotechnology
- Headquarters: Copenhagen, Denmark
- Website: www.antagtherapeutics.com/
- Total disclosed funding: $86M
- Latest round: Series A (Nov 29, 2024)
- Investors on record: 7

## About

Founded in 2017 by Mette M. Rosenkilde and Jens J. Holst and based in Copenhagen, Denmark, Antag Therapeutics ApS is a preclinical-stage biotechnology company that specializes in the treatment of related metabolic diseases. As of 2023, the company is led by its CEO, Alexander H. Sparre-Ulrich.

The company specializes in offering therapeutic peptides that are peptide-based GIP receptor antagonists’ development so that metabolic illnesses connected to diet can be monitored via infusion. This allows the healthcare sector to reduce body fat, lipid uptake, and blood flow. The primary use of these peptides is subcutaneous injection for self-administration, which focuses on treating obesity and postural orthostatic tachycardia syndrome (POTS).

## Funding rounds

- Series A, Nov 29, 2024, $86M — Versant Ventures, Pictet Group, SR One, Novo Holdings, Longview Ventures, Export and Investment Fund of Denmark, Dawn Biopharma

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A
- Pictet Group — Series A
- SR One (https://capitalatlas.ai/funds/sr-one) — Series A
- Novo Holdings — Series A
- Longview Ventures — Series A
- Export and Investment Fund of Denmark (https://capitalatlas.ai/funds/export-and-investment-fund-of-denmark) — Series A
- Dawn Biopharma — Series A